All In Biotech

Drug Trial Radar · NCT03876262

Safety and Efficacy of Annual or Biannual Doses of Moxidectin or Ivermectin for Onchocerciasis

A Randomized, Double Blind, Parallel Trial in the Democratic Republic of Congo (DRC) Comparing the Safety and Efficacy of Annual or Biannual Doses of Moxidectin or Ivermectin for Treatment of Onchocerciasis

Last checked: Nov 19, 2026Latest source record: Dec 23, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 323 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

323

Actual

Start

May 3, 2021

Primary completion

Jul 31, 2024

Study completion Jan 1, 2026

Sponsor

Lead sponsor
Medicines Development for Global HealthAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Mar 15, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 12 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary purpose of this phase 3b study is to determine the safety and efficacy of moxidectin administration twice a year, compared to once a year, in maintaining undetectable levels in skin of O. volvulus microfilaria in skin, the parasite that causes river blindness. Secondary purposes are to determine the effectiveness of moxidectin compared to ivermectin once or twice a year in maintaining undetectable levels, or reducing levels, of skin microfilaria.

Conditions

  • Onchocerciasis

Interventions

  • MoxidectinDrug

    2mg tablets, encapsulated for blinding

  • IvermectinDrug

    3mg tablets, encapsulated for blinding

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Proportion of moxidectin annual and biannual recipients with sustained microfilarial response at month 12Time frame: Up to 12 months
  2. Incidence and severity of adverse eventsTime frame: Up to 36 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Centre de Recherche pour les Maladies Tropicales Negligees

    Rethy, Ituri, Democratic Republic of the Congo

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.